Randomized trial investigates IL-34's role in bone erosion among rheumatoid arthritis, suggesting potential therapies.
Background The crosstalk between fibroblast-like synoviocytes (FLS) and macrophages forms a self-reinforcing vicious feedback loop in the rheumatoid arthritis (RA) immune microenvironment. Upregulated interleukin-34 (IL-34) levels in RA patients correlate with RA severity. This study investigated the roles and mechanisms of IL-34-mediated FLS-macrophage crosstalk in osteoclastogenesis-associated bone erosion in RA. Methods IL-34 expression in the RA serum and synovial samples and its correlation with disease severity and bone erosion were assessed. Primary FLS were transfected with IL-34 overexpression plasmids or short hairpin RNA (shRNA) targeting IL-34, and cell proliferation, migration, invasion and apoptosis were examined. Then, conditioned medium (CM) from these FLS were incubated with THP-1-differeniated macrophages to evaluate macrophage migration and polarization. FLS, M1 macrophages, and their cocultures were respectively treated with recombinant human IL-34 (rhIL-34), and these CM were incubated with peripheral blood mononuclear cells (PBMCs). Receptor activator of NF-κB ligand (RANKL) concentration and osteoclast differentiation were determined. Additionally, a collagen-induced arthritis mouse model was established and treated with IL-34 neutralizing antibody. The arthritis score, paw swelling, histopathological analysis micro-CT analysis were conducted. Results Upregulated serum IL-34 level in RA patients was correlated with disease severity and bone erosion. IL-34 overexpression facilitated proliferation, migration and invasion and inhibited apoptosis in FLS. Moreover, CM from IL-34-overexpressing FLS promoted macrophage recruitment and M1 polarization. In contrast, IL-34 silencing showed the opposite results. rhIL-34-stimulated FLS-macrophage coculture exhibited higher RANKL production and enhanced osteoclast differentiation. However, RANKL inhibitor denosumab abolished these effects. IL-34 blockade attenuated RA severity, synovial hyperplasia, macrophage M1 polarization, inflammatory infiltration, and bone erosion in CIA mice. Conclusion IL-34 accelerates RA progression by regulating FLS-macrophage crosstalk to amplify bone erosion through RANKL-dependent osteoclastogenesis. We suggest that IL-34 blockade as a promising therapeutic strategy for concurrently alleviating synovial hyperplasia, inflammation, and bone erosion in RA.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: